Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9195780 | 0.84 | PLK1 (0.52) | HCAR3KDM4EALDH1A1MAPTGAA | |
| SCHEMBL3396257 | 0.83 | KDM4E (0.52) | HCAR3KDM4EALDH1A1MAPTGAA | |
| SCHEMBL9194517 | 0.83 | ABL1 (0.47) | KDM4EGLACNR1 | |
| SCHEMBL8715959 | 0.83 | CNR2 (0.58) | HCAR3KDM4EALDH1A1MAPTGAA | |
| SCHEMBL2910695 | 0.81 | PLK1 (0.43) | KDM4EGAAHSD17B10CNR2CNR1 | |
| SCHEMBL28875089 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1MAPTGAAHSD17B10 | |
| SCHEMBL5928710 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1MAPTGAAHSD17B10 | |
| SCHEMBL15635588 | 0.79 | KDM4E (0.46) | HCAR3KDM4EALDH1A1MAPTGAA | |
| SCHEMBL12723401 | 0.79 | RIPK1 (0.47) | HCAR3KDM4EALDH1A1MAPTGAA | |
| SCHEMBL5272294 | 0.78 | KDM4E (0.68) | KDM4EALDH1A1MAPTGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286215-A1 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | 2010-11-11 | — | — | US | disclosed |
| EP-2185504-A2 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009030887-A2 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286215-A1 | BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | LTC4S, LTB4R2, LTB4R | HCAR3 214/4885KDM4E 3526/4885ALDH1A1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.